Abivax

Abivax is a clinical-stage biotechnology company founded in 2013 and headquartered in France. The company is focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Currently, Abivax is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. The company also plans to initiate a Phase 2a clinical trial of obefazimod in patients with Crohn’s disease. Obefazimod, an investigational, orally administered, once-daily therapy, is considered a potentially differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response. If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers. Abivax's last investment was a €150.00MPost-IPO Debt investment on 21 August 2023. The investment was made by Claret Capital, Kreos Capital, and Heights Capital Management. The company operates within the industries of Biotechnology, Health Care, Health and Wellness.